Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia

Clinical Cancer Research

Volumn 14, Issue 14, 2008, Pages 4392-4399

  Quintás Cardama, Alfonso ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ABELSON KINASE; AP 24534; AP 24564; AT 9283; AURORA KINASE INHIBITOR; BCR ABL PROTEIN; BCR ABL1 PROTEIN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; DCC 2036; DORAMAPIMOD; DP 2494; DP 2629; FINGOLIMOD; IMATINIB; ISOLEUCINE; KW 2449; NILOTINIB; PANOBINOSTAT; PHA 739358; PHOSPHOTRANSFERASE INHIBITOR; PYRIDINE DERIVATIVE; SGX 393; TANESPIMYCIN; TG 100598; TG 101114; TG 101477; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; VE 465; XL 228; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ALOPECIA; APOPTOSIS; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; ENZYME ACTIVITY; EPIGENETICS; GENE MUTATION; HUMAN; INJECTION SITE REACTION; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT PLANNING; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 51649120694     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0117     Document Type: Review

References (81)

1. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A 1990;87:6649-53.
2. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature 1990;344:251-3.
3. Daley GQ. Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-30.
4. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2: 561-6.
5. Scappini B, Onida F, Kantarjian HM, et al. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer 2002;94:2653-62.
6. Gambacorti-Passerini C. le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997;23:380-94.
7. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.
8. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25.
9. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI- 571 inhibition of abelson tyrosine kinase. Science 2000;289:1938-42
10. Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002;62:4236-43.
11. Hantschel 0. Nagar B, Guettler S, et al. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 2003; 112:845-57.
12. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112:831-43.
13. Quintas-Cardama AG, DL, Kantarjian H, et al. Mutational analysis of chronic myeloid leukemia (CML) clones reveals heightened BCR-ABL1 genetic instability and wild-type BCR-ABL1 exhaustion in patients failing sequential imatinib and dasatinib therapy [abstract 1938]. Blood 2007;110.
14. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS- 354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65: 4500-5.
15. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640-53.
16. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, EGF receptor kinases. Proc Natl Acad Sci U S A 2005;102:11011-6.
17. Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004;18:1321-31.
18. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293:876-80.
19. Lowenberg B. Minimal residual disease in chronic myeloid leukemia. N Engl J Med 2003;349: 1399-401.
20. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003;101:4611-4.
21. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphiachromosome-positive leukaemias. Lancet Oncol 2003;4:75-85.
22. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-41.
23. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354: 2542-51.
24. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41.
25. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61.
26. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401.
27. Azam M, Nardi V, Shakespeare WC, et al. Activity of dual SRC-ABL inhibitors highlights the role of BCR ABL kinase dynamics in drug resistance. Proc Natl Acad Sci U S A 2006;103:9244-9.
28. Druker BJ, Sawyers CL. Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001:344:1038-42.
29. Sherbenou DW, Wong MJ, Humayun A, et al. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia 2007;21 489-93.
30. Chu S, Xu H, Shah NP, et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005; 105:2093-8.
31. Willis SG, Lange T, Demehri S. et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy Blood 2005;106:2128-37.
32. Khorashad JS, Anand M, Marin D, et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib Leukemia 2006;20:658-63.
33. Bradeen HA, Eide CA, O'Hare T et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006;108:2332-8.
34. Muller M, Erben P, Schenk T. et al. Response to dasatinib after imatinib failure according to type of preexisting BCR-ABL mutations [abstract 748]. Blood 2006;108.
35. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003;4: 842-54.
36. Hoover R, Harding, MW. Synergistic activity of the Aurora kinase inhibitor MK-0457 (VX-680) with idarubicin. Ara-C, inhibitors of BCR-ABL [abstract 1384]. Blood 2006;108.
37. Shah N, Skaggs B, Branford S, et al. The most common dasatinib-resistant BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia are sensitive to VX-680: Rationale for early combination kinase inhibitor therapy [abstract 2175] Blood 2006;108.
38. Cheetham GM, Charlton PA. Golec JM, Pollard JR. Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680. Cancer Lett 2007;251:323-9.
39. Young MA, Shah NP, Chao LH, et al. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006;66:1007-14.
40. Giles F, Cortes J, Bergstrom DA, et al. MK-0457, a novel Aurora kinase and BCR-ABL inhibitor, is active against BCR-ABL T3151 mutant chronic myelogenous leukemia [abstract 163]. Blood 2006;108.
41. Tauchi T, Akahane D, Nunoda K, et al. Combined effects of a pan-Aurora kinase inhibitor MK-0457 and dasatinib against T315I mutant form of BCR-ABL: in vitro and in vivo studies [abstract 805]. Blood 2007:110.
42. Zhang W. Inhibition of the drug-resistant T315I mutant of BCR-ABL. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2006.
43. Shah N, Kasap C, Paquette R, et al. Targeting drugresistant CML and Ph+-ALL with the spectrum selective protein kinase inhibitor XL228 [abstract 474]. Blood 2007;110.
44. Gontarewicz A, Balabanov S, Keller G, et al. Simultaneous targeting of Aurora kinases and Bcr-Abl by the small molecule inhibitor PHA-739358 is effective in imatinib-resistant mutations including T3151 [abstract 1042]. Blood 2007;110.
45. Modugno M, Casale E, Soncini C, et al. Crystal structure of the T3151 Abl mutant in complex with the aurora kinases inhibitor PHA-739358. Cancer Res 2007;67:7987-90.
46. Paquette R, Shah NP, Sawyers CL, et al. PHA- 739358, an Aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL [abstract 1030]. Blood 2007;110.
47. Cortes J, Roboz GJ, Kantarjian H, et al. A phase I dose escalation study of KW-2449, an oral multikinase inhibitor against FLT3, ABL, FGFR1, and Aurora in patients with relapsed/refractory AML, treatment resistant/intolerant CML, ALL, MDS [abstract 909]. Blood 2007;110.
48. Tauchi T, Akahane D, Nunoda K, et al. Activity of a novel Aurora kinase inhibitor, VE-465, against T315I mutant form of BCR-ABL: In vitro and in vivo studies [abstract 1358]. Blood 2006;108.
49. Ravandi F, Foran J, Verstovsek S, et al. A phase I trial of AT9283, a multitargeted kinase inhibitor, in patients with refractory hematological malignancies [abstract 904]. Blood 2007;110.
50. Van Etten R, Chan WW, Zaleskas VM, et al. DCC- 2036: a novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T315I in vitro and in a CML mouse model [abstract 463]. Blood 2007;110.
51. Regan J, Breitfelder S, Cirillo P, et al. Pyrazole ureabased inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J Med Chem 2002;45: 2994-3008.
52. Kuma Y, Sabio G, Bain J, Shpiro N, Marquez R, Cuenda A. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem 2005;280:19472-9.
53. Fabian MA, Biggs WH lll, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-36.
54. O'Hare T, Druker BJ. BIRB-796 is not an effective ABL(T315I) inhibitor. Nat Biotechnol 2005;23: 1209-10;author reply 1210-1.
55. Zhu H. Enzymatic and cellular inhibition of BCR/ABL T315I by a novel src/ABL inhibitor [abstract 3771]. Proc Am Assoc Cancer Res 2006.
56. Zhu H. Addressing BCR/ABL resistance: evolving dasatinib to a novel inhibitor of the T3151 BCR/Abl mutation [abstract 3254]. Proc Am Assoc Cancer Res 2007.
57. Rivera V, Xu Q. Wang F, et al. Potent antitumor activity of AP24534, an orally active inhibitor of Bcr-Abl variants including T315I, in in vitro and in vivo models of chronic myeloid leukemia (CML) [abstract 1032]. Blood 2007;110.
58. O'Hare T, Eide CA, Tyner JW, et al. SGX70393 inhibits Bcr-AbfT 3151 in vitro and in vivo and completely suppresses resistance when combined with nilotinib or dasatinib [abstract 535]. Blood 2007;110.
59. Gorre ME, Sawyers CL. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 2002;9:303-7.
60. George P, Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005;105:1768-76.
61. Nguyen TK, Rahmani M, Gao N, et al. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate. Clin Cancer Res 2006;12:2239-47.
62. Cortes J, Quintas-Cardama A, Garcia-Manero G, et al. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer 2007;110:2000-6.
63. Copland M, Pellicano F, Richmond L, et al. BMS- 214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008;111: 2843-53.
64. Cancelas JA, Lee AW, Prabhakar R, Stringer KF, Zheng Y, Williams DA. Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization. Nat Med 2005;11:886-91.
65. Thomas EK, Cancelas JA, Chae HD, et al. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell 2007;12: 467-78.
66. Neviani P. Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005;8: 355-68.
67. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-40.
68. Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosomepositive acute lymphocytic leukemia. J Clin Invest 2007;117:2408-21.
69. Tang R, Faussat AM, Majdak P, et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther 2006;5:723-31.
70. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, et al. Phase l/ll study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007;109: 248-55.
71. Khoury H, Michallet M, Corm S, et al. Safety and efficacy study of subcutaneous homoharringtonine (SC HHT) in imatinib (IM)-resistant chronic myeloid leukemia (CML) with the T315I mutation initial report of a phase ii trial [abstract 1050]. Blood 2007;110.
72. Kuroda J, Puthalakath H, Cragg MS, et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A 2006;103:14907-12.
73. Kuroda J, Kimura S, Andreeff M, et al. ABT-737 is a useful component of combinatory chemotherapies for chronic myelogenous leukemias with diverse drug resistance mechanisms [abstract 808]. Blood 2007;110.
74. Rahmani M, Nguyen TK, Dent P, Grant S. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol Pharmacol 2007;72: 788-95.
75. Khorasanizadeh S. The nucleosome: from genomic organization to genomic regulation. Cell 2004:116: 259-72.
76. Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005;280:26729-34.
77. Fiskus W, Pranpat M, Bali P, et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Ablexpressing human leukemia cells. Blood 2006;108: 645-52.
78. Fiskus W, Pranpat M, Balasis M, et al. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells. Clin Cancer Res 2006;12:5869-78.
79. Dai Y, Chen S. Venditti CA, et al. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia (CML) cells sensitive and resistant to imatinib mesylate [abstract 1041]. Blood 2007;110.
80. Okabe S, Tauchi T, Nakajima A, et al. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. Stem Cells Dev 2007;16:503-14.
81. Nimmanapalli R, Fuino L, Bali P, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or - refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003;63:5126-35.